Petros Pharmaceuticals PTPI short squeeze
Petros Pharmaceuticals PTPI is possibly about to explode again as the short position increases as PPS is ticking up. Pay attention to PTPI as this stock may skyrocket
Petros PTPI company summary
Company Name: Petros Pharmaceuticals, Inc.
Ticker: (PTPI)
Exchange: NASDAQ
Short Squeeze Article: HERE
Petros PTPI Company Summary:
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.
Why is it red HOT?
The NEWS:
Petros reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use.
What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?
The Short Squeeze
Look HERE at our buddies over at Fintel.io. This stock has a big short position and could go crazy!
PTPI 5 Day Chart
PTPI 5 Day Analysis
The convergence point is coming Traders! All signs are pointing to a short squeeze! It is coming late Friday or Monday! Once PTPI breaks $2.82 & $2.90, boom like a rocket ship!
PTPI 1 Day Chart
1 Day Analysis
You can clearly see the $2.82 resistance. Get ready traders because I’ve been following PTPI for a while and I can hear the juice machine warming up for the BIG squeeze.
Freeline Therapeutics FRLN report
Freeline Therapeutics Holdings plc (FRLN) is going down down down but is the there a reversal coming soon?
Freeline Therapeutics FRLN Company Summary
Company Name: Freeline Therapeutics Holdings plc
Ticker: FRLN
Exchange: NASDAQ
Website: https://www.freeline.life/
Freeline Therapeutics FRLN Company Summary
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.
Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream.
The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.
Freeline Therapeutics FRLN News
Jan. 06, 2022
Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FLT201 as an investigational gene therapy for the treatment of Gaucher disease Type 1.
“The FDA clearance of this IND is an important milestone for FLT201, which is the first AAV-mediated gene therapy for patients with Gaucher disease Type 1 in the clinic,” said Michael Parini, Chief Executive Officer of Freeline. “Our FLT201 program harnesses our unique scientific platform capabilities – our highly potent, proprietary AAVS3 capsid, robust CMC and pre-clinical data across all our programs, and our advanced protein engineering capabilities – to develop a potentially transformative treatment for patients suffering from Gaucher disease. The entry of our third program into the clinic is important validation of the advantage of Freeline’s portfolio approach to development.”
Freeline Therapeutics FRLN Stock Chart
FRLN Analysis
There is resistance at $2.10 and $2.15 and this stock will continue to go down unless it can correct and breakout of the two resistance points. The news is great, so I expect a consolidation soon and a correction. Make sure to keep this on your radar.
China Xiangtai Food PLIN Bottom Play
China Xiangtai Food PLIN is poised for a possible breakout, take a look at the summary below.
China Xiangtai Food Co., Ltd. (PLIN) Summary
Company Name: China Xiangtai Food Co., Ltd
Ticker: PLIN
Exchange: NASDAQ
Website: https://irplin.com.
China Xiangtai Food Co., Ltd. (PLIN) Summary
China Xiangtai Food Co., Ltd., engages in agricultural business. The Company is actively deploying emerging technologies including crypto asset mining and blockchain technologies with diversified expansion strategy. The current operations are in the United States, Canada and China.
China Xiangtai News
Jan. 6, 2022
Entered into a purchase agreement (the “Agreement”) with a global Bitcoin mining hardware company to purchase 686 spot Bitcoin miners that are worth US$6 million. The top-tier newly manufactured miner with a hash rate of 92 TH/s are expected to ramp up the hash rate of the Company’s miner fleet by over 63,000 TH/s.
Dec. 20, 2021
Announced that it has launched its U.S. operation with the establishment of its U.S. headquarter office in the prestigious Seagram Building in New York City. PLIN’s establishment of the New York office marks an important milestone within Company’s global expansion strategy as a U.S. listed company.
The U.S. operation will be led by its senior executive team in the U.S.. This strategic move is to set the foundation for the Company’s diversified growth initiative within the U.S., as well as to demonstrate the management team’s ambition and determination of creating long term value to shareholders and investors.
PLIN 1 Day Chart
PLIN Technical Analysis
$1.35 is the PPS traders should be looking for it to beat. I like the news, crypto is hot and the stock is going to run, it’s just a matter of time. Put it on your watchlist, this is a potential XXX% gainer!
Kaival Brands KAVL ready to breakout?
Kaival Brands KAVL has been in a bearish trend and it is possible that there has been a reversal. Take a look at this chart.
Kaival Brands KAVL Company Summary
Company Name: Kaival Brands Innovations Group, Inc.
Ticker: KAVL
Exchange: NASDAQ
Website: www.ir.kaivalbrands.com.
Kaival Brands Company Summary:
Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets.
Our vision is to develop internally, acquire, own, or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor.
KAVL News
Dec. 14, 2021
Announced today that 80% of adult participants in a recent survey of e-cigarette users and cigarette smokers in the United Kingdom (“U.K.”) preferred the BIDI® Stick over their current options.
Dec. 6, 2021
Announced that it has partnered with Koupon to create an electronic engagement program involving Koupon’s digital promotion platform. The partnership will offer customers who purchase the BIDI® Stick—a premium electronic cigarette—digital opportunities based on their purchases.
KAVL 1 Day Chart
Kaival Brands Innovations Group, Inc. (KAVL) analysis
This stock is trying it’s best to break the second level of resistance and it should move once it does. Keep an eye on the $.78 PPS, it is a resistance point that is important!
LM Funding America LMFA ready?
LM Funding America LMFA has been bearish for almost a month and I believe it is almost ready to reverse it’s trend, stay tuned! To review the bird’s eye view, keep on reading.
LM Funding America LMFA Company Summary
Company Name: LM Funding America, Inc.
Ticker: LMFA
Exchange: NASDAQ
Website: https://lmfunding.com/
LM Company Summary:
LM Funding America LMFA, together with its subsidiaries, is a technology-based specialty finance company that provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado and Illinois, by funding a certain portion of the associations’ rights to delinquent accounts that are selected by the Associations arising from unpaid Association assessments.
The Company has also announced that it is entering the cryptocurrency mining business through a new subsidiary, US Digital Mining and Hosting Co., LLC.
What was the last news for LMFA?
Oct. 19, 2021
Announced the closing of its previously announced underwritten public offering of 6,315,780 shares of its common stock and warrants to purchase up to 6,315,780 shares of the Company’s common stock. Each share of common stock was sold in a unit together with one common warrant at a public offering price of $4.75 per unit, for gross proceeds of approximately $30 million, before deducting underwriting discounts and offering expenses.
The common warrants have an exercise price of $5.00 per share of common stock, are immediately exercisable and will expire five years from the date of issuance. In addition, LM Funding has granted the underwriters a 45-day option to purchase up to an additional 947,367 shares of common stock and/or common warrants to purchase up to 947,367 shares of common stock, at the public offering price less discounts and commissions, of which Maxim Group LLC has exercised its option to purchase an additional 947,367 warrants.
LMFA 1 Month Chart
LMFA 1 Day Chart
LM Funding Technical Analysis
This stock has been falling like a tree in British Columbia Canada, for a long time, almost a month. What comes up must comes down and this has come down, so I’m looking for a bounce soon.
It reversed it’s bearish trend yesterday but it may be a head fake. Make sure you always wait for a double confirmation before considering investing. The second reversal point is $4.60. As a reminder, a second reversal is not a guarantee of a bullish move, it is a signal. Trade carefully always and with stop losses.
China Tower (CHWRF) Update
China Tower Corporation Limited is possibly about to breakout.
Company Name: China Tower Corporation Limited
Ticker: CHWRF
Exchange: OTC
Company Summary:
is a China-based telecommunications tower infrastructure service provider. The Company mainly has three business segments.
China Tower 5 Day Chart
China Tower Corporation 1 Day Chart
China Tower Corporation Limited (CHWRF) technical analysis
China Tower Corporation Limited (CHWRF) is up 10% and has broken out of its low. Keep a careful eye on this one because of the low volume it will be a tough one to get out of cause it is thinly traded.
DatChat NASDAQ: DATS breakout?
DatChat NASDAQ: DATS is down 10% today and we are patiently waiting for a signal of a reversal. Let’s take a close look at the high level view of DATS.
DatChat NASDAQ: DATS Company Snapshot:
Company Name: DatChat , Inc.
Ticker: DATS
Exchange: NASDAQ
Website: https://www.datchat.com/
DatChat Company Summary:
DatChat Inc. is a blockchain, cybersecurity, and social media Company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others.
The DatChat Messenger & Private Social Network presents technology that allows users to change how long their messages can be viewed before or after users send them, prevents screenshots, and hides encrypted photos in plain sight on camera rolls. DatChat’s patented technology offers users a traditional texting experience while providing control and security for their messages.
With DatChat Messenger, a user can decide how long their messages last on a recipient’s device, while feeling secure that, at any time, they can delete individual messages or entire message threads, making it like the conversation never happened.
DatChat in the News:
Jan. 03, 2022
Announced the appointment of Mark Mathis as its first Chief Blockchain Architect. The Chief Blockchain Architect position will focus on aligning the Company’s strategic initiatives with the increasing adoption of blockchain technology primarily through development and integration within the DatChat ecosystem.
Nov. 30, 2021
Announced the release of the Nirad Points Rewards Program (NRD), with the first 1 million users receiving 10,000 NRD Points.
DATS 5 Day Chart
DATS 1 Day Chart
DATS Technical Analysis
There is an old adage, what goes up must come down and nothing other than gravity displays this universal truth more than the stock market. The market overall fluctuates by the minute and individual stocks fluctuate constantly.
DATS is no different, it has great news and moves up and then the longs take their profits and the short pile on, boom, it goes down. Rinse and repeat, over and over again! I’ve been watching this stock for a while and I have a hunch that it is about to consolidate and run.
I do believe this stock is sound fundamentally but the scared ones are still taking profit but I believe, when they are done, this could run. Stay tuned and wait for a double confirmation reversal.
Breakout for Mainz Biomed MYNZ?
Mainz Biomed MYNZ develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. So, our traders have the ability to invest and feel good about helping the world while simultaneously investing!
The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.
The top 4 reasons Mainz Biomed B.V. (NASDAQ: MYNZ) is primed for a Massive breakout!
#1 MYNZ is Undervalued
#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!
#3 Mainz Biomed Is Generating Revenue
#4 Philanthropic Investing feels good
Before we go over the top 4 reasons, let’s get acquainted with Mainz Biomed.
Company Name: Mainz BioMed
Ticker: MYNZ
Exchange: NASDAQ
Website: https://mainzbiomed.com/investors/
Mainz Biomed MYNZ Company Summary:
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.
ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval.
Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.
[thrive_leads id=’9846′]
Why did it go up over 30% in just 21 trading days?
DECEMBER 7th, 2021
At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany
Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days. For more Info HERE
DECEMBER 14th, 2021
Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany with their 5,500 labs.Mainz Biomed announced a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe’s leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer. For More Info HERE
Now that we have a good understanding of why MYNZ is up 30%, let’s go over the top 4 reasons Mainz Biomed could be ready for a massive breakout!
#1 MYNZ is Undervalued
#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!
#3 Mainz Biomed B.V. Is Generating Revenue
#4 Philanthropic Investing feels good
#1 MYNZ is in a Multi-Billion Dollar Industry
Mainz Biomed has a Market Cap of $121 Million but when you look at other companies that are in the space, you can see the value in this diamond in the rough. I am very excited to see this kind of potential priced at such a low PPS and with a very small float at 12 Million shares outstanding.
Furthermore, Mainz plans on starting the FDA process shortly after their public listing. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to a market potential of over 52 million tests per year. 1 Can you imagine what will happen to the price per share of MYNZ when they get approved? Let’s look at one of their competitors to see what actually did happen!
Take a look at Mainz Biomed’s competitor Exact Sciences Corporation NASDAQ
Today, the top non-invasive colorectal screening test technology is manufactured by Exact Sciences (NASDAQ:EXAS), which is a perfect success story that Mainz BioMed is currently seeking to recreate. EXAS is valued at $17 BILLION and trades at $78 PPS! Could you imagine if MYNZ is trading at those PPS in the near future? That would be almost 700% gains, like turning $10,000 into $80,000.
I do apologize, I tend to get excited about companies that are showing massive potential in a philanthropic industry. Invest and possibly make money while saving lives, it’s the cornerstone of the capitalism that Adam Smith promoted. Not this crony Capitalism!
Did you see the EXAS’ share price back in 08’ it fell to less than one dollar. Essentially, investors were basically saying Exact was worthless.But in June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.
However, it was in 2014 when the FDA approved Cologuard for use as a non-invasive colorectal cancer screening test, and the test’s inclusion in multiple national guidelines that truly made the stock take off.
Hmm… Isn’t Mainz seeking FDA approval! See the correlation? I do and you should too.
For investors of EXAS who got in as recently as mid-2016 have already seen their investment grow nearly 20x in just over 5 years. Today it’s worth nearly $17 billion USD.
20x Returns, that $10,000 would be $200,000
Here is the kicker, Mainz Biomed’s ColoAlert is designed to be easier to administer than Exact Sciences ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. This is truly cutting edge medical testing at a fraction of the PPS of Exact Science.
MYNZ other competitor is Genescopy a privately help company making some moves
The reason I mention Geneoscopy is because this story is relevant, take a look at the investment level, $100M++!
Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced November 17th the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity.
The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners. HERE
That is an example of just how large this industry is and how much money is available to fund it. It’s cancer and it has affected almost everyone in one way or the other.
#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!
MYNZ 1 Month Chart Technical Analysis
As you can see the trend is very Bullish and has consolidated since the December 21st-December 28th run. The 30% run last month that started December 6th was very controlled and on moderate volume.
Next, let’s look at the 5 day chart to see what is happening lately.
MYNZ 5 Day Chart Technical Analysis
I’ve been waiting on this reversal and I was betting it would happen today and literally in the final hour of trading it happened. I love this chart! As you see from the month chart above a bullish move and then consolidation with a slight bearish lean. Consequently, I’ve been waiting for a confirmation of a reversal. As MYNZ reached $10.43 it confirmed the reversal and this may just take off like a rocket ship.
If you think the stock chart is good, wait until you see why. MYNZ is generating revenue and the street is watching.
#3 Mainz Biomed B.V. Is Generating Revenue
ColoAlert has received CE accreditation and is approved for sale in Europe.1 European sales will provide near-term revenue potential, while they prepare for entry into the US market. Just last month, Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test.
This is significant, DTC (direct to consumer) test to see if you have cancer which will allow you to catch it early and have a 90% survival rate. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.
ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance. The fact that Mainz Biomed is generating revenue in Europe and will be entering the US market with FDA approval is a massive sign for things to come. Make sure you keep MYNZ on your watchlist because the potential is substantial.
#4 Philanthropic Investing – possibly turn an amazing profit while helping people
It is rare for investors to be able to possibly have a home run return on an investment while helping to alleviate senseless deaths with the 2nd most deadly form of cancer.Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.
90% survival rate if detected early, guess what, ColoAlert detects early stage colon cancer. There is a solution and it is ready to come to market in the USA with FDA approval.
Why is Mainz Biomed your cake and icing for investors?
- ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer. Far less senseless deaths in regards to colon cancer!
- Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. Protecting intellectual property is important for market capitalization!
- Mainz Biomed MYNZ is developing proprietary genetic testing methods for pancreatic cancer. Once the distribution channel is developed, offering multiple products creates more than one revenue stream!
- Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. 1
Let’s recap why Mainz Biomed MYNZ could be, THE massive breakout of 2022!
#1 MYNZ is Undervalued
#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!
#3 Mainz Biomed B.V. Is Generating Revenue
#4 Philanthropic Investing feels good
It is a rare opportunity in this world to have this kind of investment opportunity while also funding the act of saving lives. This is an easy fix, detect the 2nd most dangerous form of cancer early and you have a 90% survival rate. ColoAlert is the answer, we just need to stop what we are doing and place it on your watchlist, today!
Happy Trading and remember, never try to catch a falling knife!
1 https://mainzbiomed.com/investors/
Disclaimer
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, MYNZ. Small Cap Exclusive has been hired by Awareness Consulting for a period beginning on January 4, 2021 to publicly disseminate information about (MYNZ) via website and email. We have been compensated $13,500 USD. We will update any changes to our compensation.
Read full disclaimer here.